Clinical Trials are the gold standard study design for evaluating the benefits and risks associated with medical interventions. A group of distinguished panelists will discuss the future of clinical trials and how they will be impacted by increased knowledge of biomarkers resulting in personalized medicine, calls for greater pragmatism and systematic benefit:risk assessment, greater availability of supplementary data, and increasing costs.

Moderator

• Scott Evans, Harvard University

Panelists:

• Ralph D’Agostino, Boston University
• Cyrus Mehta, Cytel Inc.
• Bob O’Neill, FDA
• Marc Pfeffer, Brigham and Women’s Hospital
• David Schoenfeld, Massachusetts General Hospital

Light Dinner 6:00pm; Panel Discussion 7:00pm